Compared to the small cell or squamous cell lung cancer patients, more LUAD patients could benefit from the target therapies including but not limited to EGFR TKIs, VEGFR inhibitors, or c‐MET inhibitors. This evidence concerns the gene EGFR and squamous cell lung carcinoma.